Anacor Reports Second Quarter 2015 Financial Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended June 30, 2015.
“2015 continues to be a very productive year for Anacor. We recently announced that crisaborole, our novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults, achieved statistically significant results on all primary and secondary endpoints in two Phase 3 pivotal studies and demonstrated a safety profile consistent with previous studies
Help employers find you! Check out all the jobs and post your resume.
“2015 continues to be a very productive year for Anacor. We recently announced that crisaborole, our novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults, achieved statistically significant results on all primary and secondary endpoints in two Phase 3 pivotal studies and demonstrated a safety profile consistent with previous studies
Help employers find you! Check out all the jobs and post your resume.